Roche Holding AG (OTCMKTS:RHHBY - Get Free Report) has been given a consensus recommendation of "Hold" by the six brokerages that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation, one has given a buy recommendation and one has issued a strong buy recommendation on the company.
RHHBY has been the subject of a number of research reports. Morgan Stanley assumed coverage on Roche in a research note on Wednesday. They issued an "equal weight" rating for the company. Sanford C. Bernstein upgraded Roche to a "strong-buy" rating in a research report on Thursday, January 30th.
Check Out Our Latest Report on RHHBY
OTCMKTS RHHBY opened at $41.05 on Wednesday. Roche has a 12 month low of $29.20 and a 12 month high of $42.43. The company has a current ratio of 1.26, a quick ratio of 0.97 and a debt-to-equity ratio of 0.86. The company's fifty day moving average price is $36.95 and its two-hundred day moving average price is $38.33.
Several institutional investors and hedge funds have recently modified their holdings of RHHBY. Hancock Whitney Corp boosted its holdings in Roche by 6.8% during the fourth quarter. Hancock Whitney Corp now owns 23,516 shares of the company's stock valued at $820,000 after acquiring an additional 1,496 shares during the period. HighPoint Advisor Group LLC lifted its stake in shares of Roche by 2.8% in the fourth quarter. HighPoint Advisor Group LLC now owns 11,091 shares of the company's stock valued at $387,000 after buying an additional 304 shares during the period. SVB Wealth LLC acquired a new stake in Roche during the fourth quarter worth about $555,000. Altrius Capital Management Inc lifted its position in shares of Roche by 0.3% in the 4th quarter. Altrius Capital Management Inc now owns 183,448 shares of the company's stock worth $6,399,000 after acquiring an additional 603 shares during the period. Finally, Verity Asset Management Inc. grew its holdings in shares of Roche by 26.8% during the 4th quarter. Verity Asset Management Inc. now owns 8,036 shares of the company's stock worth $280,000 after purchasing an additional 1,697 shares in the last quarter.
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Roche, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.
While Roche currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.